跳至主要内容
临床试验/NCT01724918
NCT01724918终止2 期

Lacosamide IV and EEG/EKG (LIVE) Study

Lawson Health Research Institute4 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
72
试验地点
4
主要终点
Change in the number of interictal spikes

研究概览

简要总结

The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram) rhythms (or brain rhythms) in subjects with focal seizures and the tolerability of those doses by patients. In addition, this study will assess the effect of IV lacosamide on EKG (electrocardiogram), a test which checks for problems with the electrical activity of the heart.

详细描述

The impact of antiepileptic drugs on the EEG can vary from marked to none. A small number of AEDs also affect the EKG. Lacosamide is a new AED that selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. Information is lacking about the effect of lacosamide on brain and heart rhythms.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
  • Adult patients 18-65 years
  • Diagnosis of focal epilepsy
  • Continuous EEG and video monitoring
  • Continuous EKG
  • Active EEG showing frequent spikes, electrographic or clinical seizures

排除标准

  • Subject has no IV access.
  • Subject is hemodynamically unstable.
  • Previous use of Lacosamide
  • Primary generalized epilepsy
  • Non-epileptic seizures
  • No significant cardiac, renal or hepatic disease
  • No cardiac arrhythmias including heart block
  • Subject is a pregnant or lactating woman.

研究组 & 干预措施

100 mg IV

Other

100 mg IV lacosamide infused over 30 minutes

干预措施: Lacosamide (Drug)

200 mg IV

Other

200 mg IV lacosamide infused over 30 minutes

干预措施: Lacosamide (Drug)

400 mg IV

Other

400 mg IV lacosamide infused over 30 minutes

干预措施: Lacosamide (Drug)

结局指标

主要结局

Change in the number of interictal spikes

时间窗: One hour before and after drug

次要结局

  • Change in frequency and quantity of background EEG rhythms(One hour before and after drug)
  • Change in EKG (QT, PR interval and heart rhythm)(One hour before and after drug)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rick McLachlan

Principal Investigator

Lawson Health Research Institute

研究点 (4)

Loading locations...

相似试验